768-44-5

Basic information

• Product Name: 5-Ethyl-2-methylpyridine 1-oxide
• Synonyms: 5-Ethyl-2-methylpyridine 1-oxide;5-ethyl-2-methyl-1-oxidopyridin-1-ium
• CAS NO: 768-44-5
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.179
• Mol File: 768-44-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 296.2°Cat760mmHg
• Flash Point: 132.9°C
• Appearance: /
• Density: 0.98g/cm³
• PKA: pK1:-1.288(+1) (25°C)
• CAS DataBase Reference: 5-Ethyl-2-methylpyridine 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Ethyl-2-methylpyridine 1-oxide(768-44-5)
• EPA Substance Registry System: 5-Ethyl-2-methylpyridine 1-oxide(768-44-5)

Safety Data

• Hazardous Substances Data: 768-44-5(Hazardous Substances Data)

Usage

General Description

5-Ethyl-2-methylpyridine 1-oxide, also known as ethylmethylpyridine oxide, is a chemical compound with the molecular formula C8H11NO. It is a heterocyclic compound with a pyridine ring that is substituted with an ethyl group and a methyl group. 5-Ethyl-2-methylpyridine 1-oxide is commonly used as a building block in the synthesis of other organic compounds and as a reagent in various chemical reactions. It is also used as a ligand in coordination chemistry and as a precursor in the production of pharmaceuticals and agrochemicals. Additionally, 5-Ethyl-2-methylpyridine 1-oxide has potential applications in research and development for its unique chemical properties and potential biological activities.

InChI:InChI=1/C8H12NO/c1-3-8-5-4-7(2)9(10)6-8/h4-7H,3H2,1-2H3/q+1

Upstream product

• 104-90-5 5-ethyl-2-methyl-pyridine 

Downstream Products

• 1131-20-0 5-Ethyl-2-methyl-4-nitropyridin-N-oxid 
• 98952-72-8 5-ethyl-2-methylpyridine-4-carbonitrile 
• 21913-84-8 5-ethyl-pyridine-2-carboxaldehyde 
• 768-61-6 2-hydroxymethyl-5-ethyl pyridine 
• 98488-99-4 5-ethyl-4-bromo-2-methyl-pyridine 
• 152009-92-2 4,5-diethyl-2-methyl-pyridine 
• 90873-00-0 4-(Acetylamino)-5-ethyl-2-methylpyridin 
• 15742-82-2 4-Amino-5-(hydroxymethyl)-2-methylpyridin 
• 127915-47-3 5-Acetyl-4-amino-2-methylpyridin 
• 91842-97-6 5-Acetyl-4-(acetylamino)-2-methylpyridin 
• 127915-50-8 4-Amino-6-methyl-3-pyridincarbonsaeure 
• 5350-64-1 4-Amino-5-ethyl-2-methylpyridin 
• 104-90-5 5-ethyl-2-methyl-pyridine 
• 106411-71-6 2-[(3aS,7aS)-7a-Ethyl-2-oxo-3-p-tolyl-2,3,3a,7a-tetrahydro-4H-oxazolo[4,5-b]pyridin-(5Z)-ylidene]-N-p-tolyl-acetamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor

The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.

BASIC AMINE COMPOUND AND USE THEREOF

Novel amine compounds which are represented by the following formula (1) and efficacious against diseases such as a viral infectious disease with HIV, rheumatism, and cancer metastasis; typically, A 1 and A 2 represent a hydrogen atom or a substitutable monocyclic or polycyclic heteroaromatic ring and W represents a substitutable benzene ring or any group represented by the following formula (10) or (11): where X represents O, CH 2 , C(=O), NR 11 , or CHR 35 and D represents a group represented by the following formula (6): where Q represents a single bond, NR 12 , or a group represented by the formula (13): and Y represents a group represented by the following formula (7) : where z represents a substitutable monocyclic or polycyclic aromatic ring; and B represents -NR 25 R 26 ; and R 1 to R 26 in the above formulae represent a hydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group.